Recent Articles from GlobeNewswire

SALT LAKE CITY, Nov. 03, 2026 (GLOBE NEWSWIRE) -- rPlus Energies today announced the closing of a revolving credit facility of up to $450 million to support the continued development and construction of its near-term pipeline of solar and energy storage projects across the American West. The facility provides both funded borrowing capacity and letters of credit.

Collaboration closes the loop between AI drug design and human biology: Chemveda designs and makes the molecules, VivoSim’s NAMkind™ 3D human liver and intestine models show which ones are safe to advance, in weeks rather than years

Pomeroy brings more than 35 years of thermal, energy, and technology leadership experience, including growing a business to more than $200 million in revenue

HOUSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Sysco Corporation (NYSE:SYY) (“Sysco” or the “company”) today announced financial results for its 13-week first fiscal quarter ended September 26, 2026.

Company reaffirms fiscal 2027 adjusted EPS and local volume guidance

Progressing commercial initiatives and advancing value unlock strategy in the Benelux

Seven abstracts sponsored by Recor Medical presented at TCT 2026 highlight expanding clinical evidence for ultrasound renal denervation.

Trial fully enrolled ahead of schedule

With 60,000 customers enrolled, Sunrun’s distributed power plant has been activated daily for more than two weeks in a row this October to deliver critical power during island-wide energy shortfalls

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced its participation in the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Phoenix, Arizona. The Company’s participation includes two invited presentations and a preclinical poster showcasing the breadth and continued evolution of its platform.

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following investor conferences before the end of 2026:

SmartScale platform aligns with the FDA's Operation TrialBlazer initiative

Nuclear News’ recognition highlights Waples’ technical leadership and contributions to advancing innovative nuclear waste disposal solutions

Naples, Italy and Hamilton, Bermuda, Nov. 03, 2026 (GLOBE NEWSWIRE) -- The RoyaLand Company Ltd. (the “Company” or “RoyaLand”) (OTCQB: RLNDF), a Bermuda holding company focused on creating immersive, fantasy-based royalty-themed games and growing its Italian professional football club Savoia 1908 FC (“Savoia” or the “Club”), today announced a landmark moment for Savoia, which has advanced to the quarter-finals of the Coppa Italia for the first time in its 118-year history. Goals from Pasquale Riccardi and Matteo Polizzi secured a 2-0 victory over Sorrento at home on October 27, delivering a significant milestone for the Club. The Coppa Italia is an annual Italian domestic knock out competition played by 60 teams. The Copa Italia Serie C winner qualifies for the promotion playoff round for potential advancement to Serie B.

Custom vehicles and Gentex tech for automotive OEMs, accessory programs, and the aftermarket

ORLANDO, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Innventure, Inc. (NASDAQ: INV) (“Innventure”) today announced it will release its third quarter 2026 financial results after market close on Thursday, November 12, 2026. Management will host a conference call on the day of the release at 5:00 pm ET to discuss the results.

Global integration gives advertisers access to native, real-time AU reporting across web and CTV, plus automated attention-threshold optimization

BriteCore positioned highest for Ability to Execute among Challengers and second-highest for Ability to Execute among all evaluated platforms

NAARDEN, The Netherlands and MIAMI, Nov. 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:

Pensa Actions AI automates store walks and guides where time is best spent for in-store activities

PHILADELPHIA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced its participation in the following upcoming investor conferences:

Independent ratings support Serenova Re's continued growth and partnership development in Japan and international markets

With embedded AI to accelerate the decommission-to-archive lifecycle, the Clearsense platform helps health systems retire legacy applications faster, reduce costs and free up resources for innovation

Hong Kong, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cre8 Enterprise Limited (Nasdaq: CRE) (“Cre8” or the “Company”), a Hong Kong-based integrated financial printing service provider, announced today that its wholly owned subsidiary, Cre8 Incorporation Limited, has completed the acquisition of 100% of the issued shares of Lingxpert Language Services Limited ("LingXpert"), a company incorporated in Hong Kong, which provides translation services in Hong Kong. LingXpert started operations on March 9, 2011. The acquisition is intended to strengthen Cre8’s capacity to support clients on both IPO and non-IPO engagements.

EMERYVILLE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in November and December:

CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today announced that management will participate in the following investor conferences in November.

HOUSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Intuitive Machines, Inc. (Nasdaq: LUNR) ("Intuitive Machines," and together with its subsidiaries, the "Company"), a leading space technology, infrastructure, and services company, today announced that it has been selected by NASA's Jet Propulsion Laboratory (JPL) to provide the spacecraft platform and system-level integration for FALCON-RADAR, an Earth observation mission that will study clouds and convection from space.

U.S.-based facility begins pilot production of critical battery materials using ACT-ion’s proprietary ACT-ivate™ process, strengthening the domestic supply chain

BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced its participation in the following upcoming investor conferences:

Executive-level forum brings together leaders from regulatory, research, government, and public-benefit organizations

Built on Atsign Platform, EdgeAI secures distributed systems with up to 88x higher encryption throughput on Intel Xeon processors and 60x on Intel Core Ultra processors, as reported in the collaborative solution brief

PRINCETON, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced that management will present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference, to take place November 9-11, 2026.

The partnership gives BairesDev teams direct technical support from Anthropic, backed by Claude builds already running in production for clients.

AVENTURA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Dataprana (“the Company”) has announced the launch of its new brand identity, highlighting its expanding role in the digital infrastructure landscape. Dataprana is reinforcing its position in advancing data center development through a power-first approach to site selection, efficient speed-to-market execution, and scalable solutions designed to support the growing needs of the AI economy. As part of this transition, the company is also redeveloping its corporate website, with the new site expected to launch in the coming weeks.

Strategic appointment brings deep technology and telecommunications industry expertise to accelerate Alianza Crux adoption and scale its two-sided ecosystem of service providers and conversational AI developers.

Seasonal Initiative Builds on Established Relationship with Leading Regional Grocery Retailer

PETAH TIKVA, Israel, Nov. 03, 2026 (GLOBE NEWSWIRE) -- TurboGen Ltd. (NASDAQ:TRBG) (TASE:TURB) (“TurboGen” or the “Company”), a developer of combined heat and power systems based on multifuel microturbines, today announces that it has completed the first assembly of its propriety TR2000 system, a 20 kilowatt (“kW”) unit designed for defense applications as well as residential buildings and other civilian projects. Upon completion of the TR2000 system’s assembly, the Company began testing the system internally.

PALO ALTO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that two moderated posters and three posters on acoramidis and transthyretin amyloid cardiomyopathy (ATTR-CM), along with one BridgeBio-supported poster presentation led by Abbott Laboratories, will be shared at the American Heart Association (AHA) Scientific Sessions 2026, taking place in Chicago, Illinois on November 6-9, 2026. The data further strengthen the differentiated clinical profile of acoramidis, reinforcing it as the first-line treatment of choice for individuals with ATTR-CM. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.

IMS Legal Strategies (IMS) announces a new expansion of its fast-growing Life Care Planning services and a continuation of its overall growth strategy, with the acquisition of Medical & Life Care Consulting Services (MLCC), the well-established, multi-discipline firm based in Massachusetts that works throughout New England and nationally. All members of the MLCC team will join IMS.

LOUISVILLE, Ky., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Creative Realities, Inc. ("Creative Realities," "CRI," or the "Company") (NASDAQ: CREX), a leading provider of digital signage and media solutions, announced today that it will release its financial results for the three months ended September 30, 2026 before the market open on Monday, November 16, 2026. A conference call to review the results is scheduled for Monday, November 16, 2026, at 9:00 am Eastern Time, which will include prepared remarks and materials from management followed by a live Q&A. The call will be hosted by Rick Mills, Chairman and Chief Executive Officer, Tamra Koshewa, Chief Financial Officer and George Sautter, Chief Strategy Officer.

CEO Michael Halstead to participate in a fireside chat on November 9, 2026 at 3:00 p.m. EDT

IRVINE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will participate at upcoming investor conferences:

Decades of experience growing dual-use defense technology companies 

WAYNE, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that members of its management team will present at the Stifel 2026 Healthcare Conference on Tuesday, November 10, 2026, at 9:20 a.m. ET.

Starting November 4, MyHabit members can order $2 drinks, $4 Santa Barbara Loaded Fries and $6 BBQ Tossed Crispy Chicken Bites exclusively through Habit’s digital ordering channels

IMS Legal Strategies (IMS) announces a new expansion of its fast-growing services, and a continuation of its overall growth strategy, with the acquisition of Medical & Life Care Consulting Services (MLCC), the well-established, multi-discipline firm based in Massachusetts that works throughout New England and nationally. All members of the MLCC team will join IMS.

Connecting Corporate News with North America's Media Landscape

Tel Aviv, Israel, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Nexera Technologies Ltd (“Nexera” or the “Company”) (Nasdaq: NEXR, NEXRW), today announced that, as previously announced by its subsidiary, Fort Technology Inc. (Nasdaq: FRTT, TSXV: FORT) (“Fort”), the TSX Venture Exchange ("TSXV") has approved the voluntary delisting of Fort’s common shares from the TSXV. The voluntary delisting from the TSXV will not affect the listing of the Fort’s common shares on the Nasdaq Capital Market (the "Nasdaq"), which will continue to trade on the Nasdaq under the symbol FRTT.

Lead pan-coronavirus program expected to file CTA/IND in 2H 2027Optimized lead candidate shows potential for once-weekly dosing in preclinical studiesCash on balance sheet of $8.1 million at September 30, 2026

WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that Ron Renaud, President and Chief Executive Officer, and additional members of the management team will participate in the following investor conferences:

NORTH BETHESDA, Md., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Xometry, Inc. (NASDAQ: XMTR), the global AI-native marketplace connecting buyers and suppliers of custom manufacturing, today announced its financial results for the third quarter ended September 30, 2026.

New research from MIT Sloan School of Management and MIT FutureTech suggests that the public, investors, and regulators lack information about whether companies are prepared for AI risks.

NEW HAVEN, Conn., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on November 1, 2026, Invivyd granted seven newly hired non-executive employees options to purchase an aggregate of 175,000 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan. 

Updated BEAM-302 Phase 1/2 Clinical Data Presented at ERS Demonstrated Durable Increases in Functional AAT and Reductions in Mutant Z-AAT; Completion of Dosing in the Global Pivotal Cohort Expected in First Half of 2027

WATERTOWN, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a biotechnology company pioneering a new class of medicines against challenging targets in oncology and immunology & inflammation, today announced that management will participate in the Guggenheim Third Annual Healthcare Innovation Conference, Stifel 2026 Healthcare Conference, and Jefferies 2026 London Healthcare Conference.

LONDON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Evestia Clinical (“the Company”), a leading independent global specialist Contract Research Organization (CRO), today announced the acquisition of Emtex Life Science (“Emtex”), a specialist regulatory medical writing company headquartered in Belgium. The acquisition strengthens Evestia Clinical's presence across Europe and further enhances the Company's global, full-service clinical research solutions for biotech innovators and pharmaceutical companies.

Preston Road office joins the firm’s McKinney and Frisco locations and offers the firm’s monthly-fee billing model

NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced the third quarter 2026 performance and quarterly rebalancing of the OTCQX® indexes, including the OTCQX Canada Index and the OTCQX Dividend Index.

Third Quarter 2026 Highlights

MENLO PARK, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis and hidradenitis suppurativa, today announced its participation and presentation at multiple upcoming conferences:

Internet, Everywhere, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Shopify announced today financial results for the quarter ended September 30, 2026. Shopify achieved 32% revenue growth (32% in constant currency) and a 22% free cash flow margin.

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced its participation in Guggenheim’s 3rd Annual Healthcare Innovations Conference being held at the Intercontinental Boston. Management will participate in a fireside chat on Tuesday, November 10, 2026, at 3:00 pm Eastern Time and will also participate in one-on-one investor meetings.

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will participate in three upcoming investor conferences:

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced that it will host a conference call on Tuesday, November 10, at 8:00 a.m. ET to discuss its financial results and provide a corporate update for the third quarter ended September 30, 2026.

Net Revenues Increased by 17.0% Year-over-Year to RMB17.9 Billion

CLEVELAND, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three- and nine-months ended September 30, 2026.

THE WOODLANDS, Texas, Nov. 03, 2026 (GLOBE NEWSWIRE) -- LGI Homes, Inc. (NASDAQ: LGIH) today announced financial results for the third quarter and the nine months ended September 30, 2026.

COMPANY STRENGTHENS NEUROSCIENCE LEADERSHIP WITH WELTRUZA™ LAUNCH AND STRATEGIC ADDITION OF BXCL-501

CHICAGO and VANCOUVER, British Columbia, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. (Green Thumb) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis company with a portfolio of best-in-class brands and owner of RISE Dispensaries, today announced the opening of RISE Dispensary Mulberry, located at 6751 North Church Ave., Mulberry, FL 33860, on Wednesday, November 4, giving Polk County patients a new place to shop close to home. Marking RISE’s first location in Polk County, the new dispensary expands access to quality medical cannabis for patients in Mulberry, nearby Lakeland and surrounding communities, while strengthening Green Thumb’s growing presence across Central Florida.

NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced financial results for the third quarter ended September 30, 2026. Financial results in this release, including all comparisons to prior year periods, reflect continuing operations only.

Company to host investor conference call and webcast at 4:30 p.m. ET.

BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced that Malte Peters, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at Guggenheim’s 3rd Annual Healthcare Innovation Conference on Tuesday, November 10, 2026 at 8:00 AM EST.